COVID-19：Ube Industries to Begin Supplying Intermediates for Avigan® Tablet

By flu, Drugs, Pharmaceutical

COVID-19：Ube Industries to Begin Supplying Intermediates for Avigan® Tablet

TOKYO, April 22, 2020 —

Ube Industries, Ltd.

announced today that it will begin manufacturing and supplying the critical intermediates that constitute the active pharmaceutical ingredient (API) core skeleton for the influenza antiviral drug Avigan® Tablet (generic name: favipiravir), which was developed by FUJIFILM Toyama Chemical Co., Ltd.

Avigan

is expected to offer potential benefits for the treatment of coronavirus disease 2019 (COVID-19) amid a global pandemic.

The Japanese government

is fast-tracking clinical trials and approvals for Avigan while also supporting the establishment of a framework for manufacturing in Japan.

UBE INDUSTRIES,LTD.

https://www.ube-ind.co.jp/ube/en/news/2020/20200422_01.html

More from tokioX :

  1. COVID-19: Avigan, improvement by early administration: Recovery rate 87% -Director of Ministry of Health, Thailand
  2. Taiwan’s government organization decides to stockpile Fujifilm’s anti-influenza drug “Avigan® Tablet”
  3. COVID-19: CMIC starts Avigan clinical trial / manufacturing: Phase III trial CRO / CDMO
  4. COVID-19: Status Report of “Avigan”: Japanese Society of Infectious Diseases
  5. Kaneka Agrees to Supply Active Pharmaceutical Ingredients for Avigan® Tablet
  6. Fujifilm accelerates production of its influenza antiviral drug “Avigan® Tablet” for COVID-19.
  7. COVID-19: Clinical Trials for Avigan Started in the US: 3 Massachusetts Hospitals